PROVE-IT TIMI 22

PROVE-IT TIMI 22 is a landmark clinical trial in the field of Cardiology and Pharmacology, specifically focusing on the management of Acute Coronary Syndrome (ACS). The trial was conducted by the Thrombolysis in Myocardial Infarction (TIMI) study group, hence the name PROVE-IT TIMI 22.

Overview

The PROVE-IT TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction) trial was a randomized, open-label, multicenter trial that compared the efficacy of two different statin therapies in patients with recent Acute Coronary Syndrome (ACS). The trial aimed to determine whether intensive lipid-lowering therapy with Atorvastatin (80 mg daily) would result in a better clinical outcome than standard therapy with Pravastatin (40 mg daily).

Methodology

The trial enrolled 4,162 patients who had been hospitalized for an ACS within the preceding 10 days. Patients were randomly assigned to receive either 80 mg of atorvastatin per day or 40 mg of pravastatin per day. The primary endpoint was a composite of death from any cause, Myocardial Infarction (MI), documented unstable angina requiring rehospitalization, revascularization (performed at least 30 days after randomization), and stroke.

Results

The results of the PROVE-IT TIMI 22 trial showed that intensive statin therapy with atorvastatin 80 mg was superior to pravastatin 40 mg in preventing cardiovascular events in patients with recent ACS. The primary endpoint occurred in 22.4% of patients in the atorvastatin group and 26.3% of patients in the pravastatin group. This represented a significant 16% relative risk reduction with atorvastatin therapy.

Implications

The findings of the PROVE-IT TIMI 22 trial have had a significant impact on the management of patients with ACS. The trial provided strong evidence in favor of intensive statin therapy in these patients, leading to a shift in clinical practice towards the use of high-dose statin therapy in patients with ACS.

See Also

• Acute Coronary Syndrome
• Atorvastatin
• Pravastatin
• Myocardial Infarction
• Thrombolysis in Myocardial Infarction